Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
72.21 USD | +0.47% | -0.96% | +24.91% |
Apr. 29 | Boston Scientific Insider Sold Shares Worth $719,562, According to a Recent SEC Filing | MT |
Apr. 26 | Daiwa Adjusts Price Target on Boston Scientific to $81 From $73 | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With an expected P/E ratio at 49.92 and 40.25 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+24.91% | 106B | A- | ||
+8.33% | 219B | B | ||
+6.72% | 183B | B- | ||
+10.18% | 132B | B- | ||
-0.95% | 62.09B | A- | ||
+10.56% | 50.8B | B+ | ||
+4.81% | 50.88B | B+ | ||
-0.24% | 40.64B | A | ||
+1.22% | 35.71B | - | ||
+24.99% | 31.59B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BSX Stock
- Ratings Boston Scientific Corporation